Index RUT P/E - EPS (ttm) -3.68 Insider Own 64.79% Shs Outstand 33.18M Perf Week 31.38%
Market Cap 958.61M Forward P/E - EPS next Y -2.86 Insider Trans 0.94% Shs Float 20.89M Perf Month 48.80%
Income -220.40M PEG - EPS next Q -0.79 Inst Own 37.40% Short Float 26.51% Perf Quarter 121.37%
Sales 2.91M P/S 329.42 EPS this Y 33.78% Inst Trans -0.70% Short Ratio 17.77 Perf Half Y 57.97%
Book/sh 2.07 P/B 7.82 EPS next Y 8.23% ROA -53.94% Short Interest 5.54M Perf Year 131.85%
Cash/sh 4.33 P/C 3.73 EPS next 5Y - ROE -115.71% 52W Range 3.81 - 22.50 Perf YTD 94.46%
Dividend Est. - P/FCF - EPS past 5Y -44.65% ROI -141.47% 52W High -28.18% Beta 0.17
Dividend TTM - Quick Ratio 7.06 Sales past 5Y 19.85% Gross Margin -205.46% 52W Low 324.15% ATR (14) 1.79
Dividend Ex-Date - Current Ratio 7.06 EPS Y/Y TTM 30.22% Oper. Margin -8137.82% RSI (14) 67.91 Volatility 24.70% 13.34%
Employees 224 Debt/Eq 0.32 Sales Y/Y TTM 74.00% Profit Margin -7571.35% Recom 1.67 Target Price 23.88
Option/Short Yes / Yes LT Debt/Eq 0.27 EPS Q/Q 44.48% Payout - Rel Volume 1.92 Prev Close 17.23
Sales Surprise -97.69% EPS Surprise -1841.03% Sales Q/Q 179.91% Earnings Aug 14 BMO Avg Volume 311.52K Price 16.16
SMA20 36.69% SMA50 49.84% SMA200 64.04% Trades
Volume 597,969 Change -6.21%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-09-24 Upgrade RBC Capital Mkts
Sector Perform → Outperform
$9 → $21
Dec-15-23 Downgrade BofA Securities
Buy → Neutral
$8
Dec-07-23 Downgrade H.C. Wainwright
Buy → Neutral
$11 → $7
Nov-09-22 Resumed Jefferies
Buy
$61 → $55
Oct-17-22 Initiated JP Morgan
Neutral
$27
Aug-29-22 Initiated BofA Securities
Buy
$34
Dec-13-21 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$51
Nov-05-21 Upgrade Wedbush
Neutral → Outperform
Aug-26-21 Initiated Morgan Stanley
Overweight
$100
Jan-29-21 Initiated RBC Capital Mkts
Outperform
$121
Jan-19-21 Reiterated H.C. Wainwright
Buy
$88 → $114
Dec-22-20 Downgrade Wedbush
Outperform → Neutral
Jul-17-20 Initiated Robert W. Baird
Outperform
$90
Jul-01-20 Initiated H.C. Wainwright
Buy
$88
May-28-20 Initiated SunTrust
Buy
$86
Apr-22-20 Initiated Wedbush
Outperform
$73
Oct-14-19 Initiated Stifel
Buy
$32
Oct-14-19 Initiated Piper Jaffray
Overweight
$26
Oct-14-19 Initiated Jefferies
Buy
$25
Oct-14-19 Initiated Guggenheim
Buy
$30
Show Previous Ratings
Sep-18-24 09:33AM
Sep-10-24 04:05PM
Aug-22-24 12:00PM
Aug-14-24 08:00AM
07:00AM
09:35AM
Loading…
Jul-12-24 09:35AM
May-29-24 07:00AM
May-10-24 02:38PM
May-09-24 07:38AM
May-08-24 10:55PM
05:55PM
04:10PM
May-07-24 07:00AM
May-03-24 10:00AM
Apr-30-24 12:00PM
08:30AM
Loading…
Apr-17-24 08:30AM
Apr-10-24 07:00AM
Mar-07-24 10:52PM
05:45PM
04:10PM
Mar-01-24 09:55AM
Feb-14-24 09:55AM
Feb-01-24 07:00AM
Jan-16-24 08:38AM
Jan-03-24 07:00AM
Dec-08-23 04:09AM
Dec-06-23 02:44AM
Dec-05-23 04:01PM
Dec-01-23 05:32AM
Nov-27-23 03:52AM
02:46AM
Loading…
Nov-22-23 02:46AM
Nov-21-23 02:48AM
Nov-16-23 09:55AM
Nov-14-23 07:28PM
Nov-13-23 04:10PM
03:49AM
Nov-07-23 07:00AM
Oct-25-23 02:46AM
Oct-23-23 02:48AM
Oct-20-23 09:29AM
Oct-05-23 07:29AM
Oct-03-23 04:05PM
(GlobeNewswire) -7.06%
-10.66%
Sep-20-23 04:36AM
Sep-06-23 07:00AM
Aug-10-23 08:59PM
Aug-03-23 05:25PM
04:10PM
Jul-05-23 06:46AM
Jul-03-23 04:01PM
Jun-30-23 09:48AM
Jun-22-23 08:14PM
07:58AM
Jun-21-23 05:17PM
Jun-02-23 05:30PM
(GlobeNewswire) +5.92%
-22.13%
Jun-01-23 07:00AM
May-31-23 07:00AM
May-30-23 07:00AM
May-25-23 11:58AM
May-12-23 10:15AM
09:05AM
May-02-23 07:00AM
Apr-28-23 11:50AM
Apr-19-23 07:00AM
Apr-13-23 04:05PM
Apr-06-23 12:23PM
Apr-01-23 09:17AM
Mar-30-23 06:05PM
04:05PM
Mar-27-23 07:00AM
Feb-02-23 07:00AM
Jan-17-23 07:00AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-11-22 10:00AM
Dec-01-22 07:00AM
Nov-16-22 06:37AM
Nov-08-22 07:00AM
Nov-03-22 10:25AM
09:05AM
Nov-02-22 04:05PM
Oct-27-22 02:06PM
Sep-06-22 07:00AM
Aug-08-22 06:45PM
04:10PM
Jul-04-22 02:04PM
Jun-01-22 07:00AM
May-20-22 12:07PM
May-10-22 07:00AM
May-09-22 04:16PM
May-06-22 07:00AM
Apr-09-22 09:35AM
Apr-06-22 04:39PM
(GlobeNewswire) +8.33%
-8.47%
Apr-05-22 04:56PM
Mar-30-22 03:06PM
02:14PM
01:29PM
11:57AM
12:56AM
Mar-29-22 11:41AM
09:00AM
IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm's product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Weber Steven PRINCIPAL ACCOUNTING OFFICER Sep 13 '24 Sale 11.54 469 5,412 25,543 Sep 17 08:58 PM Takimoto Chris H CHIEF MEDICAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 154,331 Sep 17 08:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 122,694 Sep 17 08:54 PM Schwarzer Fred CEO AND PRESIDENT Sep 13 '24 Sale 11.54 3,946 45,532 250,124 Sep 17 08:52 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Sep 13 '24 Sale 11.54 1,487 17,158 242,948 Sep 17 08:50 PM Harler Mary Beth Head, Research & Autoimmunity Sep 13 '24 Sale 11.54 1,487 17,158 163,740 Sep 17 08:44 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Sep 13 '24 Sale 11.54 925 10,673 79,104 Sep 17 08:42 PM Hambleton Julie Director Jul 25 '24 Option Exercise 1.39 15,132 21,033 17,132 Jul 29 05:45 PM Hambleton Julie Director Jul 25 '24 Sale 14.00 15,132 211,848 2,000 Jul 29 05:45 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Jun 14 '24 Sale 7.58 495 3,750 26,012 Jun 18 07:45 PM Takimoto Chris H CHIEF MEDICAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 95,818 Jun 18 07:44 PM Tahir Misbah CHIEF FINANCIAL OFFICER Jun 14 '24 Sale 7.58 1,570 11,893 88,848 Jun 18 07:43 PM Schwarzer Fred CEO AND PRESIDENT Jun 14 '24 Sale 7.58 4,164 31,544 254,070 Jun 18 07:42 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Jun 14 '24 Sale 7.58 1,106 8,378 197,769 Jun 18 07:41 PM Harler Mary Beth Head, Research & Autoimmunity Jun 14 '24 Sale 7.58 1,570 11,893 85,227 Jun 18 07:40 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Jun 14 '24 Sale 7.58 977 7,401 60,029 Jun 18 07:38 PM BAKER BROS. ADVISORS LP Director Mar 26 '24 Buy 8.26 270,000 2,230,767 3,638,533 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 28 '24 Buy 9.62 97,473 937,632 3,753,480 Mar 28 07:04 PM BAKER BROS. ADVISORS LP Director Mar 27 '24 Buy 9.24 27,844 257,170 3,664,073 Mar 28 07:04 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 13 '24 Sale 9.88 529 5,224 26,971 Mar 15 07:57 PM Weber Steven PRINCIPAL ACCOUNTING OFFICER Mar 14 '24 Sale 10.17 464 4,719 26,507 Mar 15 07:57 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 13 '24 Sale 9.88 2,889 28,529 96,923 Mar 15 07:55 PM Takimoto Chris H CHIEF MEDICAL OFFICER Mar 14 '24 Sale 10.17 2,535 25,782 94,388 Mar 15 07:55 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 13 '24 Sale 9.88 2,897 28,608 92,961 Mar 15 07:53 PM Tahir Misbah CHIEF FINANCIAL OFFICER Mar 14 '24 Sale 10.17 2,543 25,864 90,418 Mar 15 07:53 PM Schwarzer Fred CEO AND PRESIDENT Mar 13 '24 Sale 9.88 4,765 47,055 220,833 Mar 15 07:51 PM Schwarzer Fred CEO AND PRESIDENT Mar 14 '24 Sale 10.17 4,182 42,533 216,651 Mar 15 07:51 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 13 '24 Sale 9.88 2,101 20,748 173,700 Mar 15 07:49 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 14 '24 Sale 10.17 1,844 18,754 171,856 Mar 15 07:49 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 13 '24 Sale 9.88 1,798 17,756 62,584 Mar 15 07:48 PM Decker Lisa Lynn CHIEF BUSINESS OFFICER Mar 14 '24 Sale 10.17 1,578 16,049 61,006 Mar 15 07:48 PM Keyt Bruce CHIEF SCIENTIFIC OFFICER Mar 01 '24 Option Exercise 0.93 3,026 2,814 4,039 Mar 05 07:34 PM Schwarzer Fred CEO and President Dec 13 '23 Sale 5.78 17,576 101,558 102,848 Dec 15 07:20 PM Keyt Bruce Chief Scientific Officer Dec 13 '23 Sale 5.78 7,574 43,764 129,551 Dec 15 07:19 PM Decker Lisa Lynn Chief Business Officer Dec 13 '23 Sale 5.78 4,369 25,245 35,632 Dec 15 07:18 PM BAKER BROS. ADVISORS LP Director Dec 15 '23 Buy 6.55 288,007 1,887,531 3,390,323 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 6.50 157,370 1,023,157 3,123,585 Dec 15 05:32 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 5.96 87,316 520,776 2,977,836 Dec 15 05:32 PM Takimoto Chris H Chief Medical Officer Nov 29 '23 Sale 6.21 1,180 7,331 53,562 Dec 01 07:03 PM Gauthier George Chief Commercial Officer Nov 29 '23 Sale 6.21 1,180 7,331 39,642 Dec 01 07:02 PM Decker Lisa Lynn Chief Business Officer Nov 29 '23 Sale 6.21 1,180 7,331 40,001 Dec 01 07:01 PM Tahir Misbah Chief Financial Officer Nov 27 '23 Sale 5.06 1,337 6,764 49,608 Nov 29 08:49 PM Schwarzer Fred CEO and President Nov 27 '23 Sale 5.06 1,337 6,764 120,424 Nov 29 08:48 PM Keyt Bruce Chief Scientific Officer Nov 27 '23 Sale 5.06 933 4,720 137,125 Nov 29 08:47 PM Gauthier George Chief Commercial Officer Oct 02 '23 Sale 7.95 935 7,430 39,082 Oct 03 07:55 PM
Index RUT P/E - EPS (ttm) -4.28 Insider Own 9.82% Shs Outstand 73.49M Perf Week -8.12%
Market Cap 2.55B Forward P/E - EPS next Y -1.82 Insider Trans -1.92% Shs Float 66.98M Perf Month -13.01%
Income -301.06M PEG - EPS next Q -0.75 Inst Own 99.09% Short Float 18.99% Perf Quarter -4.82%
Sales 86.19M P/S 29.63 EPS this Y 35.56% Inst Trans 12.35% Short Ratio 14.73 Perf Half Y -33.19%
Book/sh 7.50 P/B 4.59 EPS next Y 45.11% ROA -53.07% Short Interest 12.72M Perf Year 40.04%
Cash/sh 5.17 P/C 6.65 EPS next 5Y - ROE -59.72% 52W Range 18.00 - 53.92 Perf YTD -5.81%
Dividend Est. - P/FCF - EPS past 5Y -65.72% ROI -53.49% 52W High -36.24% Beta 0.79
Dividend TTM - Quick Ratio 7.77 Sales past 5Y -20.00% Gross Margin 91.74% 52W Low 91.00% ATR (14) 2.04
Dividend Ex-Date - Current Ratio 7.91 EPS Y/Y TTM 14.15% Oper. Margin -372.81% RSI (14) 35.59 Volatility 5.89% 5.37%
Employees 305 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin -349.32% Recom 1.12 Target Price 68.12
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q 56.83% Payout - Rel Volume 2.74 Prev Close 35.35
Sales Surprise 73.55% EPS Surprise 51.62% Sales Q/Q - Earnings Aug 07 BMO Avg Volume 863.42K Price 34.38
SMA20 -12.05% SMA50 -9.37% SMA200 -16.83% Trades
Volume 2,364,866 Change -2.74%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-05-24 Initiated Guggenheim
Buy
$75
Dec-01-22 Initiated BofA Securities
Buy
$45
Jan-19-21 Reiterated H.C. Wainwright
Buy
$87 → $101
Oct-29-20 Reiterated H.C. Wainwright
Buy
$58 → $73
May-05-20 Initiated Barclays
Overweight
$48
Mar-19-20 Upgrade H.C. Wainwright
Neutral → Buy
$40 → $60
Mar-04-20 Downgrade H.C. Wainwright
Buy → Neutral
$40
Jan-21-20 Reiterated H.C. Wainwright
Buy
$34 → $40
Dec-04-19 Initiated H.C. Wainwright
Buy
Oct-08-19 Initiated Wedbush
Outperform
$33
Oct-08-19 Initiated JP Morgan
Overweight
$32
Oct-08-19 Initiated Goldman
Buy
$37
Oct-08-19 Initiated Cowen
Outperform
Show Previous Ratings
Sep-04-24 07:00PM
Aug-28-24 06:30AM
Aug-07-24 06:30AM
Jul-29-24 06:30AM
Jul-23-24 07:00AM
11:27AM
Loading…
Jul-12-24 11:27AM
Jul-02-24 12:12PM
Jul-01-24 06:30AM
Jun-06-24 02:34AM
02:34AM
02:34AM
Jun-05-24 07:00AM
May-23-24 05:13PM
May-08-24 07:00AM
May-03-24 03:18AM
10:53AM
Loading…
May-02-24 10:53AM
07:45AM
06:30AM
Apr-24-24 01:31PM
Apr-18-24 07:00AM
Mar-04-24 06:30AM
Feb-29-24 08:30AM
Feb-27-24 07:12AM
06:30AM
Feb-22-24 07:00AM
Feb-07-24 02:42AM
Feb-05-24 11:26PM
Jan-31-24 07:00AM
Jan-08-24 06:30AM
Dec-21-23 07:00AM
04:05PM
Loading…
Dec-08-23 04:05PM
Dec-05-23 12:32AM
Dec-04-23 04:13PM
Nov-29-23 07:00AM
Nov-28-23 04:41PM
04:03PM
(Investor's Business Daily)
Nov-27-23 06:04PM
Nov-16-23 06:30AM
Nov-02-23 07:54AM
06:30AM
Nov-01-23 06:30AM
Sep-11-23 06:30AM
Aug-02-23 06:30AM
Jun-28-23 08:29PM
Jun-07-23 07:00AM
Jun-05-23 06:30AM
May-30-23 06:30AM
May-25-23 05:05PM
(GlobeNewswire) -7.13%
-7.51%
May-24-23 07:00AM
May-11-23 12:14PM
May-03-23 06:30AM
May-02-23 07:00AM
Apr-17-23 02:32PM
02:30PM
Mar-08-23 05:05PM
Mar-01-23 07:00AM
Feb-28-23 06:30AM
Feb-27-23 06:30AM
Jan-09-23 06:30AM
Jan-03-23 07:00AM
Dec-27-22 06:30AM
Nov-22-22 07:00AM
Nov-03-22 06:30AM
Nov-01-22 11:07AM
Sep-29-22 06:30AM
Sep-10-22 10:30AM
Sep-07-22 09:56AM
09:55AM
Aug-19-22 06:30AM
Aug-04-22 06:30AM
Aug-02-22 07:00AM
Jul-15-22 06:30AM
Jul-06-22 11:38AM
Jun-13-22 09:04AM
Jun-10-22 06:30AM
Jun-09-22 07:00AM
May-27-22 09:57AM
May-26-22 05:15PM
May-25-22 12:05PM
May-24-22 08:29AM
07:59AM
07:39AM
06:30AM
May-23-22 11:24AM
May-16-22 08:30AM
May-05-22 06:30AM
Apr-19-22 06:30AM
Mar-18-22 09:15AM
Feb-24-22 06:30AM
Feb-15-22 05:03PM
Feb-08-22 01:38PM
Feb-01-22 06:30AM
Jan-12-22 01:21PM
Jan-04-22 06:30AM
Dec-27-21 09:38PM
Dec-17-21 05:38PM
Dec-15-21 08:53AM
Dec-13-21 02:24PM
11:56AM
Dec-10-21 09:24AM
Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Islam Saqib Chief Executive Officer Sep 03 '24 Sale 40.57 49,000 1,988,033 1,063,368 Sep 04 04:05 PM Edris Badreddin Chief Operating Officer Sep 03 '24 Sale 40.65 20,000 812,954 229,600 Sep 04 04:05 PM Badreddin Edris Officer Sep 03 '24 Proposed Sale 41.78 50,000 2,089,000 Sep 03 04:09 PM Saqib Islam Officer Sep 03 '24 Proposed Sale 41.58 146,000 6,070,680 Sep 03 04:07 PM Islam Saqib Chief Executive Officer Jun 03 '24 Sale 39.90 49,000 1,955,113 1,112,368 Jun 05 04:08 PM Hambleton Julie Director Jun 03 '24 Sale 40.03 4,648 186,048 4,095 Jun 05 04:08 PM Edris Badreddin Chief Operating Officer Jun 03 '24 Sale 40.07 20,000 801,372 249,600 Jun 05 04:07 PM Pichl Daniel Chief People Officer Feb 16 '24 Option Exercise 27.64 15,000 414,600 60,212 Feb 20 06:56 PM Pichl Daniel Chief People Officer Feb 16 '24 Sale 50.10 15,000 751,550 45,212 Feb 20 06:56 PM Ashar Bhavesh Chief Commercial Officer Feb 05 '24 Sale 49.32 4,834 238,435 58,154 Feb 05 09:24 PM Ashar Bhavesh Chief Commercial Officer Feb 02 '24 Sale 44.37 3,222 142,976 62,988 Feb 05 09:24 PM Pichl Daniel Chief People Officer Feb 02 '24 Option Exercise 27.64 16,250 449,150 71,393 Feb 05 09:23 PM Pichl Daniel Chief People Officer Feb 02 '24 Sale 44.32 26,181 1,160,362 45,212 Feb 05 09:23 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
